Generic Pharmaceutical Companies Rely on M&A Deals to Gain Market Share, According to Thomson Reuters
The report, Gaining Market Share in the Generic Drug Industry Through Acquisitions and Partnerships, notes that generics firms are being buffeted by heavy competition in the small molecule generics market, government mandated price cuts in Europe, and policies such as lowest price tendering.
In response, they are likely to seek M&A deals that allow them to diversify product portfolios, secure pipelines of high-quality Active Pharmaceutical Ingredients (API), expand into emerging markets, and achieve economies of scale.
"Pricing pressures in established generics markets have forced the industry to look for economies of scale in manufacturing and opportunities in emerging markets. Companies are also cutting out the middle-man and diversifying their product portfolios by moving into niche areas, including follow-on biologics," said Kate Kuhrt, director of Generics and API intelligence at Thomson Reuters. "Many generic companies have relied on M&A rather than organic growth to achieve these strategies."
A number of products losing patent protection over the next five years will be biologics and generic companies unable to develop or manufacture biologic therapies in-house will have to rely on deal-making to remain competitive.Follow-on biologics are associated with significant barriers to entry, including the cost of developing and running clinical trials, manufacturing, and marketing. The development costs for follow-on biologics are estimated to be between $100 and $200 million, compared to $1 - $5 million for a typical small-molecule generic drug.
Early access to high-quality APIs that are not infringing existing patents is critical to the success of the generics market and the cause of much M&A activity in the sector. 39 of the industry's top 50 generic companies are now backward integrated and have at least one or more subsidiaries that manufacture API.
According to the report, total M&A activity in the generic sector was valued at $6.8 billion in 2009, down from an eight year peak of $24 billion in 2008. The generic industry is currently worth an estimated $80 billion, up from $50 billion in 2004 and the largest four generic companies worldwide by sales (Teva, Mylan, Sandoz and Watson) account for nearly 50 percent of generic subscriptions in the US and nearly 40 percent worldwide. All four companies have used M&A to gain market share.
Built on more than a decade's experience supplying solutions to meet critical business challenges in the highly competitive and global generic and API markets, Thomson Reuters Newport products are now used by more than 250 of the world's leading generic companies and API manufacturers operating in 50 countries around the world. Thomson Reuters Newport Premium integrates intelligence on more than 40,000 launched products with more than 300,000 brand names containing over 10,000 different active ingredients and over 20,000 corporate groups involved with manufacturing and marketing dose products of both small molecule and biologic active ingredients.
For more information on Newport Premium, please visit: http://thomsonreuters.com/...
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.